Cargando…

Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers

BACKGROUND: Partial hepatectomy is the first option for intrahepatic mass-forming cholangiocarcinoma (IMCC) treatment, which would prolong survival. The main reason for the poor outcome after curative resection is the high incidence of early recurrence (ER). The aim of this study was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Li, Ma, Xiaohong, Liang, Meng, Li, Dengfeng, Ma, Peiqing, Wang, Sicong, Wu, Zhiyuan, Zhao, Xinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631577/
https://www.ncbi.nlm.nih.gov/pubmed/31307551
http://dx.doi.org/10.1186/s40644-019-0234-4
_version_ 1783435549912072192
author Zhao, Li
Ma, Xiaohong
Liang, Meng
Li, Dengfeng
Ma, Peiqing
Wang, Sicong
Wu, Zhiyuan
Zhao, Xinming
author_facet Zhao, Li
Ma, Xiaohong
Liang, Meng
Li, Dengfeng
Ma, Peiqing
Wang, Sicong
Wu, Zhiyuan
Zhao, Xinming
author_sort Zhao, Li
collection PubMed
description BACKGROUND: Partial hepatectomy is the first option for intrahepatic mass-forming cholangiocarcinoma (IMCC) treatment, which would prolong survival. The main reason for the poor outcome after curative resection is the high incidence of early recurrence (ER). The aim of this study was to investigate the combined predictive performance of qualitative and quantitative magnetic resonance imaging (MRI) features and prognostic immunohistochemical markers for the ER of IMCC. METHODS: Forty-seven patients with pathologically proven IMCC were enrolled in this retrospective study. Preoperative contrast-enhanced MRI and post-operative immunohistochemical staining of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor (VEGFR), P53 and Ki67 were performed. Univariate analysis identified clinic-radiologic and pathological risk factors of ER. Radiomics analysis was performed based on four MRI sequences including fat suppression T2-weighted imaging (T2WI/FS), arterial phase (AP), portal venous phase (PVP), and delayed phase (DP) contrast enhanced imaging. A clinicoradiologic-pathological (CRP) model, radiomics model, and combined model were developed. And ROC curves were used to explore their predictive performance for ER stratification. RESULTS: Enhancement patterns and VEGFR showed significant differences between the ER group and non-ER group (P = 0.001 and 0.034, respectively). The radiomics model based on AP, PVP and DP images presented superior AUC (0.889, 95% confidence interval (CI): 0.783–0.996) among seven radiomics models with a sensitivity of 0.938 and specificity of 0.839. The combined model, containing enhancement patterns, VEGFR and radiomics features, showed a preferable ER predictive performance compared to the radiomics model or CRP model alone, with AUC, sensitivity and specificity of 0.949, 0.875 and 0.774, respectively. CONCLUSIONS: The combined model was the superior predictive model of ER. Combining qualitative and quantitative MRI features and VEGFR enables ER prediction, thus facilitating personalized treatment for patients with IMCC.
format Online
Article
Text
id pubmed-6631577
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66315772019-07-24 Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers Zhao, Li Ma, Xiaohong Liang, Meng Li, Dengfeng Ma, Peiqing Wang, Sicong Wu, Zhiyuan Zhao, Xinming Cancer Imaging Research Article BACKGROUND: Partial hepatectomy is the first option for intrahepatic mass-forming cholangiocarcinoma (IMCC) treatment, which would prolong survival. The main reason for the poor outcome after curative resection is the high incidence of early recurrence (ER). The aim of this study was to investigate the combined predictive performance of qualitative and quantitative magnetic resonance imaging (MRI) features and prognostic immunohistochemical markers for the ER of IMCC. METHODS: Forty-seven patients with pathologically proven IMCC were enrolled in this retrospective study. Preoperative contrast-enhanced MRI and post-operative immunohistochemical staining of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor (VEGFR), P53 and Ki67 were performed. Univariate analysis identified clinic-radiologic and pathological risk factors of ER. Radiomics analysis was performed based on four MRI sequences including fat suppression T2-weighted imaging (T2WI/FS), arterial phase (AP), portal venous phase (PVP), and delayed phase (DP) contrast enhanced imaging. A clinicoradiologic-pathological (CRP) model, radiomics model, and combined model were developed. And ROC curves were used to explore their predictive performance for ER stratification. RESULTS: Enhancement patterns and VEGFR showed significant differences between the ER group and non-ER group (P = 0.001 and 0.034, respectively). The radiomics model based on AP, PVP and DP images presented superior AUC (0.889, 95% confidence interval (CI): 0.783–0.996) among seven radiomics models with a sensitivity of 0.938 and specificity of 0.839. The combined model, containing enhancement patterns, VEGFR and radiomics features, showed a preferable ER predictive performance compared to the radiomics model or CRP model alone, with AUC, sensitivity and specificity of 0.949, 0.875 and 0.774, respectively. CONCLUSIONS: The combined model was the superior predictive model of ER. Combining qualitative and quantitative MRI features and VEGFR enables ER prediction, thus facilitating personalized treatment for patients with IMCC. BioMed Central 2019-07-15 /pmc/articles/PMC6631577/ /pubmed/31307551 http://dx.doi.org/10.1186/s40644-019-0234-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhao, Li
Ma, Xiaohong
Liang, Meng
Li, Dengfeng
Ma, Peiqing
Wang, Sicong
Wu, Zhiyuan
Zhao, Xinming
Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
title Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
title_full Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
title_fullStr Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
title_full_unstemmed Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
title_short Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
title_sort prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631577/
https://www.ncbi.nlm.nih.gov/pubmed/31307551
http://dx.doi.org/10.1186/s40644-019-0234-4
work_keys_str_mv AT zhaoli predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT maxiaohong predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT liangmeng predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT lidengfeng predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT mapeiqing predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT wangsicong predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT wuzhiyuan predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers
AT zhaoxinming predictionforearlyrecurrenceofintrahepaticmassformingcholangiocarcinomaquantitativemagneticresonanceimagingcombinedwithprognosticimmunohistochemicalmarkers